In an interview for ESC Congress 2021, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of ...

There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional ...

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, ...

There was consistent, and significant, benefit across all categories of ejection fraction—preserved, reduced, and midrange—but especially among those with preserved ejection fraction, noted Deepak L.

Deepak L. Bhatt, MD, MPH, outlines the benefits of starting patients on sodium glucose co-transporter 2 (SGLT2) inhibitors while they are hospitalized. Results of SOLOIST proved that it was safe to ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — In this Healio exclusive, Deepak L. Bhatt, MD, MPH, provides his perspective on research ...

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, ...

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, ...

In this most recent analysis of REDUCE-IT, results show a consistent benefit favoring icosapent ethyl versus placebo irrespective of the actual statin type, said Deepak L. Bhatt, MD, MPH, of Brigham ...

In patients with heart failure and diabetes, sotagliflozin can lower glucose quite well, even when patients are facing suboptimal glomerular filtration rates, noted Deepak L. Bhatt, MD, MPH, of ...

Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 ...